327 related articles for article (PubMed ID: 17705442)
1. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Khdair A; Gerard B; Bachmeier C; Miller DW; Shekhar MP; Panyam J
Mol Pharm; 2007; 4(5):730-8. PubMed ID: 17705442
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
Khdair A; Handa H; Mao G; Panyam J
Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
[TBL] [Abstract][Full Text] [Related]
3. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules.
Chavanpatil MD; Khdair A; Panyam J
Pharm Res; 2007 Apr; 24(4):803-10. PubMed ID: 17318416
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
5. Surfactant-polymer nanoparticles enhance the effectiveness of anticancer photodynamic therapy.
Khdair A; Gerard B; Handa H; Mao G; Shekhar MP; Panyam J
Mol Pharm; 2008; 5(5):795-807. PubMed ID: 18646775
[TBL] [Abstract][Full Text] [Related]
6. Polymer-surfactant nanoparticles for sustained release of water-soluble drugs.
Chavanpatil MD; Khdair A; Patil Y; Handa H; Mao G; Panyam J
J Pharm Sci; 2007 Dec; 96(12):3379-89. PubMed ID: 17721942
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
[TBL] [Abstract][Full Text] [Related]
11. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
12. Dual-functional alginic acid hybrid nanospheres for cell imaging and drug delivery.
Guo R; Li R; Li X; Zhang L; Jiang X; Liu B
Small; 2009 Mar; 5(6):709-17. PubMed ID: 19235799
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
14. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
16. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
17. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2006 May; 27(5):409-16. PubMed ID: 16624533
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity.
Zastre JA; Jackson JK; Wong W; Burt HM
Mol Pharm; 2008; 5(4):643-53. PubMed ID: 18380467
[TBL] [Abstract][Full Text] [Related]
20. Protein release kinetics for core-shell hybrid nanoparticles based on the layer-by-layer assembly of alginate and chitosan on liposomes.
Haidar ZS; Hamdy RC; Tabrizian M
Biomaterials; 2008 Mar; 29(9):1207-15. PubMed ID: 18076987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
